📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
NEUTRAL
score: 0.25
SENTIMENT
BULLISH
TOTAL VIEWS
78
CBIO Latest News & AI Sentiment Analysis
2 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 4 ARTICLES
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
Cellution Biologics has announced a definitive agreement to acquire SimpliDerm®, a human hydrated acellular dermal matrix product, from...
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Crescent Biopharma (CBIO) completed a public offering of 9.4 million ordinary shares at $14.50 per share, alongside pre-funded warrants,...
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma (CBIO) announced pricing of an underwritten public offering consisting of 8.09 million ordinary shares at $14.50 per...
Crescent Biopharma: Intriguing Developer Of ADC / PD1-VEGF Assets May Not Be Sufficiently Derisked (NASDAQ:CBIO)
Crescent Biopharma (CBIO) faces significant clinical and commercial derisking challenges as it pursues CR-001, a PD-1 x VEGF bispecific...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice